UK-US pharma deal could lead to nearly 230,000 unnecessary deaths in England, analysis says

UK-US Pharma Trade Agreement Sparks Debate Over Public Health Impact

UK US pharma deal could lead – Recent analysis has raised concerns that a new trade agreement between the United Kingdom and the United States may result in a significant rise in preventable deaths within England. According to the study, this deal could divert billions of pounds from essential healthcare services, potentially leading to over 200,000 additional fatalities by 2036. The research, published in the British Medical Journal, highlights the financial strain on the NHS and the potential consequences for public health.

Deal Terms and Trade Context

In December, the UK reached a landmark agreement with Washington DC, committing to boost its spending on pharmaceuticals from 0.3% of GDP to at least 0.6% over the next decade. This decision was part of a broader effort to mitigate the risk of punitive tariffs threatened by former President Donald Trump. As part of the pact, the US pledged not to impose levies on British exports of medical products and equipment for the following three years. The terms of the deal, however, have sparked controversy over its long-term economic and health implications.

Trump’s earlier threats in September 2025 to impose 100% tariffs on certain medicines imported into the US created a sense of urgency for the UK to secure favorable trade conditions. The UK-US agreement was designed to ensure continued access to affordable medications while avoiding financial penalties. Yet, critics argue that the deal’s structure may not fully account for the broader effects on the NHS and other public services.

Financial Impact on the NHS

According to the analysis, the trade deal is projected to cost the NHS an additional £45 billion by the end of 2036. This amount would be used to fund the increased procurement of new medicines, which are expected to benefit patients through better treatment options. However, the study emphasizes that higher spending in one area of the healthcare system could come at the expense of others.

“In publicly funded systems with finite budgets, higher spending in one area inevitably takes away the opportunity to spend elsewhere,” noted the authors, who are affiliated with the University of York, the University of Liverpool, and Christchurch Hospital in New Zealand. They argue that redirecting funds from critical health services to pharmaceuticals could have severe consequences for patient care and health outcomes.

The research team warns that unless the UK government secures additional funding, the shift in resources may lead to 229,000 extra deaths. These fatalities are anticipated to primarily affect individuals with chronic conditions such as heart disease, respiratory illnesses, gastrointestinal disorders, and cancer. The study highlights how the NHS, which already faces budgetary pressures, could struggle to maintain its comprehensive care model without compensatory financial support.

While the UK government has hailed the agreement as a “landmark” achievement, it maintains that the NHS will not face a £45 billion shortfall. A spokesperson from the Department of Health and Social Care stated that the funding for the deal will be drawn from the budgetary reserves established during the 2025 spending review. “Future funding will be settled at the next review,” they added, underscoring the government’s confidence in its financial planning.

Despite this reassurance, the analysis challenges the assumption that avoiding tariffs will directly translate into economic benefits for the UK. The authors argue that the NHS’s increased expenditure on pharmaceuticals is likely to benefit multinational manufacturers rather than domestic industries or the broader economy. “The UK remains a net importer of medicines, meaning that much of the additional expenditure is likely to accrue to multinational manufacturers rather than remain within the NHS or wider UK economy,” the researchers explained.

The study also points out that by 2031, the projected costs of the deal are expected to surpass the total annual value of UK pharmaceutical exports to the US. This suggests that the financial commitment to the trade agreement may not be offset by the economic gains from reduced tariffs. The researchers warn that this imbalance could exacerbate existing health inequalities, particularly among vulnerable populations who rely heavily on the NHS for essential care.

Health Inequalities and Long-Term Implications

The analysis underscores the potential for the deal to widen disparities in healthcare access across different regions and demographics. Patients in underfunded areas may face longer wait times or reduced access to preventive care as resources are redirected to meet the demands of the pharmaceutical sector. This could disproportionately affect communities already struggling with health challenges and limited healthcare infrastructure.

Moreover, the researchers stress that the NHS’s finite budget means every allocation of funds has trade-offs. While new medicines can offer life-saving treatments, their procurement may come at the expense of other vital services. For instance, investments in mental health, primary care, or community health programs could be reduced, leading to cascading effects on public health.

The UK government remains optimistic about the deal, claiming it will “safeguard medicines access and drive vital investment for UK patients and business.” However, the analysis calls this perspective into question, arguing that the economic benefits of the agreement are overstated. The study highlights how the UK’s reliance on imported pharmaceuticals means the financial burden may not be evenly distributed or entirely beneficial to the NHS.

As the deal moves forward, the debate over its impact on public health is expected to intensify. Stakeholders are now scrutinizing the balance between economic incentives and healthcare priorities. With the NHS already under pressure from rising costs and staffing shortages, the question remains: will this trade agreement help or hinder the country’s ability to provide quality care to all citizens?

Broader Economic and Policy Considerations

The study’s authors advocate for a more comprehensive evaluation of the deal’s long-term effects. They emphasize that while avoiding tariffs is a strategic move, it must be paired with measures to protect the NHS from financial strain. “The assumption that avoiding Trump’s tariffs will yield economic benefits is flawed unless we ensure the NHS is adequately funded,” the researchers wrote in their analysis.

Additionally, the report highlights the need for transparency in how the additional £45 billion will be allocated. Critics argue that without clear guidelines or oversight, the funds may be used inefficiently or prioritize high-cost medications over cost-effective treatments. This could further complicate the NHS’s ability to meet the needs of its diverse patient population.

As the UK and the US continue to negotiate trade terms, the health sector is watching closely. The success of the deal will depend not only on its ability to secure pharmaceutical access but also on its capacity to maintain the integrity of the NHS’s budget and service delivery. The findings from the analysis serve as a cautionary note, urging policymakers to consider the broader implications of their economic decisions on public health outcomes.

With the trade deal set to take effect, the challenge for the UK government is to demonstrate that the financial commitment will be managed effectively. The study’s warning about the potential for avoidable deaths underscores the importance of striking a balance between economic growth and healthcare sustainability. As the NHS navigates this new landscape, the coming years will be critical in determining whether the agreement achieves its intended goals or leads to unintended consequences for public health.